- Despite Rhetoric, Obama Has Few Options to Boost Jobs
- US Debating What to Do With Billions of TARP Money Left
- US Starts Fiscal 2010 With $176 Billion Gap for October
- Forecast From Retailers: Proceed With Caution
- Cities With the Most Home Price Reductions
- Disney CFO and Parks Chief to Swap Roles
- Housing Recovery 'In Uncharted Territory': HUD Chief
- For Video Game Makers, Stakes Are High for Holidays
- In Charity Tax Filing, a Real Glimpse of Goldman Sachs
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
- Disney's CFO-Theme Park Chairman Executive Swap
- Road Rage Rants
- Housing Recovery 'Still In Uncharted Territory': HUD Secretary
- S&P Stocks Trading at New 52-Week Highs
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
MOST SHARED
- Meet The Leaders of the New Retail Revolution
- Obama Plans Jobs Summit But Not Second Stimulus
- A Public Hearing That Isn't Public
- "Friending" Big Pharma
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Disney CFO and Parks Chief to Swap Roles
- For Video Game Makers, Stakes Are High for The Holidays
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Smoking on Rise Again: More US Adults Lighting Up
Text Size 
Biomet, a maker of hip and knee replacement products, [BMET
Loading...
()
] has agreed to be acquired by a private equity consortium for about $10.9 billion in cash.
The buyers include Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and the Texas Pacific Group, along with one of Biomet's founders, Dane A. Miller.
Shareholders are being offered $44 a share, a 27% premium to Biomet's price on April 3, the trading day before news surfaced that the company was a takeover target. Biomet started looking for a buyer with the help of Morgan Stanley on April 6.
The buyers said they will use a combination of their own cash and borrowed funds from Bank of America and Goldman Sachs to finance the takeover.
The board of Biomet voted in favor of the transaction, which is subject to shareholder approval and antitrust clearance.
Biomet said the transaction is expected to be complete by Oct. 31, and the company's stock will be delisted from the Nasdaq Stock Market.
Last week, UBS analyst Kristen M. Stewart wrote in a report that a private equity buyout wouldn't be justified at more than $43 per share.
Separately, Biomet said it is delaying the release of its fiscal second-quarter financial results because of a continuing review of its stock options practices since 1996. But the company did disclose that its unaudited sales for the quarter were $520.3 million.
Print
Email
- CNBC is blogging a talk given by Warren Buffett and Bill Gates to students at Columbia University.
- They may have wrecked their company or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes